ISDA

Entry Detail

PDB ID:

7QK0

Keywords:

TRANSCRIPTION

Title:

Crystal structure of human BCL6 BTB domain in complex with compound 12a

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli BL21

PDB Version:

Deposition Date:

2021-12-17

Release Date:

2022-06-15

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.96 Å

R-Value Free:

0.21

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 61 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:B-cell lymphoma 6 protein
Chain IDs:A
Chain Length:144
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P41182 Pfam ID:PF00651

Ligand Molecules

DMS

EBL

EDO

Primary Citation

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo .

Huckvale, R, Harnden, A.C, Cheung, K.J, Pierrat, O.A, Talbot, R, Box, G.M, Henley, A.T, de Haven Brandon, A.K, Hallsworth, A.E, Bright, M.D, Akpinar, H.A, Miller, D.S.J, Tarantino, D, Gowan, S, Hayes, A, Gunnell, E.A, Brennan, A, Davis, O.A, Johnson, L.D, de Klerk, S, McAndrew, C, Le Bihan, Y.V, Meniconi, M, Burke, R, Kirkin, V, van Montfort, R.L.M, Raynaud, F.I, Rossanese, O.W, Bellenie, B.R, Hoelder, S.Show

J.Med.Chem. 65 8191 8207 (2022)

PMID: 35653645 DOI: 10.1021/acs.jmedchem.1c02175

Abstact

The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader CCT369260 to CCT373566, a highly potent probe suitable for sustained depletion of BCL6 in vivo. We observed a sharp degradation SAR, where subtle structural changes conveyed the ability to induce degradation of BCL6. CCT373566 showed modest in vivo efficacy in a lymphoma xenograft mouse model following oral dosing.

Legend

Protein

Chemical

Disease

Primary Citation of related structures